For more information about how these drugs compare, see this article
However, they are not the same compound
Some online sources sell "research-grade" peptides, which are not intended for human injection and can be unsafe
Blue Cross Blue Shield of Michigan GLP-1 Coverage Changes Explained Understanding the New Coverage Changes As of August 1, 2024, Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network (BCN) are altering their coverage for GLP-1 receptor agonists, which include popular weight loss medications like Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)
Association of glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: a meta-analysis of randomized controlled trials
Angela Tran, D.O., at Med-Fit Medical Weight Loss, provides virtual support during weight loss journeys